CANF logo

Can-Fite BioPharma Ltd.

CANF
Healthcare|Biotechnology|IL
$1.62
+0.02 (+1.25%)
Tangible Book / Share
$2.62
Cash / Share
$3.80
Next Earnings Report
Apr 1, 2027
EPS est. -$0.80 · Revenue est. $202.0K
Financing Filings (last 12 months)
8
Shelf registrations / offering prospectuses — latest Oct 9, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
Nov 6, 2026 · GlobeNewsWire
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
Nov 2, 2026 · GlobeNewsWire
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Oct 26, 2026 · GlobeNewsWire
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Sep 9, 2026 · GlobeNewsWire
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Sep 8, 2026 · GlobeNewsWire
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Sep 2, 2026 · GlobeNewsWire
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Sep 2, 2026 · GlobeNewsWire
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Aug 17, 2026 · GlobeNewsWire
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Aug 12, 2026 · GlobeNewsWire

SEC Filings (116)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 2, 20266-KForeign issuer reportDocumentIndex
Oct 26, 20266-KForeign issuer reportDocumentIndex
Oct 9, 2026EFFECTDocumentIndex
Oct 9, 2026EFFECTDocumentIndex
Oct 9, 2026424B3Offering prospectusDocumentIndex
Sep 25, 2026F-3Shelf registrationDocumentIndex
Sep 25, 2026F-3/AShelf registrationDocumentIndex
Sep 11, 2026EFFECTDocumentIndex
Sep 11, 2026EFFECTDocumentIndex
Sep 10, 2026DDocumentIndex
Sep 9, 20266-KForeign issuer reportDocumentIndex
Sep 8, 2026POS AMDocumentIndex
Sep 8, 2026POS AMDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 3, 20266-KForeign issuer reportDocumentIndex
Sep 2, 20266-KForeign issuer reportDocumentIndex
Sep 2, 20266-KForeign issuer reportDocumentIndex
Aug 28, 2026F-3Shelf registrationDocumentIndex
Aug 17, 20266-KForeign issuer reportDocumentIndex
Aug 12, 20266-KForeign issuer reportDocumentIndex
Aug 3, 20266-KForeign issuer reportDocumentIndex
Jul 20, 20266-KForeign issuer reportDocumentIndex
Jul 14, 20266-KForeign issuer reportDocumentIndex
Jul 6, 20266-KForeign issuer reportDocumentIndex
Jul 1, 20266-KForeign issuer reportDocumentIndex
Jun 26, 20266-KForeign issuer reportDocumentIndex
Jun 22, 20266-KForeign issuer reportDocumentIndex
Jun 17, 20266-KForeign issuer reportDocumentIndex
Jun 4, 20266-KForeign issuer reportDocumentIndex
Jun 2, 20266-KForeign issuer reportDocumentIndex
May 28, 20266-KForeign issuer reportDocumentIndex
May 18, 20266-KForeign issuer reportDocumentIndex
May 13, 20266-KForeign issuer reportDocumentIndex
Apr 30, 20266-KForeign issuer reportDocumentIndex
Apr 23, 20266-KForeign issuer reportDocumentIndex
Apr 3, 2026EFFECTDocumentIndex
Apr 3, 2026424B3Offering prospectusDocumentIndex
Mar 31, 2026EFFECTDocumentIndex
Mar 31, 2026EFFECTDocumentIndex
Mar 31, 2026F-3Shelf registrationDocumentIndex